PT2858646T - Di-hidronaftiridinas e compostos relacionados úteis como inibidores de cinase para o tratamento de doenças proliferativas - Google Patents

Di-hidronaftiridinas e compostos relacionados úteis como inibidores de cinase para o tratamento de doenças proliferativas

Info

Publication number
PT2858646T
PT2858646T PT128783214T PT12878321T PT2858646T PT 2858646 T PT2858646 T PT 2858646T PT 128783214 T PT128783214 T PT 128783214T PT 12878321 T PT12878321 T PT 12878321T PT 2858646 T PT2858646 T PT 2858646T
Authority
PT
Portugal
Prior art keywords
dihydronaphthyridines
treatment
kinase inhibitors
compounds useful
related compounds
Prior art date
Application number
PT128783214T
Other languages
English (en)
Inventor
A Petillo Peter
L Flynn Daniel
D Kaufman Michael
Original Assignee
Deciphera Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deciphera Pharmaceuticals Llc filed Critical Deciphera Pharmaceuticals Llc
Publication of PT2858646T publication Critical patent/PT2858646T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
PT128783214T 2012-06-07 2012-06-07 Di-hidronaftiridinas e compostos relacionados úteis como inibidores de cinase para o tratamento de doenças proliferativas PT2858646T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12878321.4A EP2858646B1 (en) 2012-06-07 2012-06-07 Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
PCT/US2012/041378 WO2013184119A1 (en) 2012-06-07 2012-06-07 Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
PT2858646T true PT2858646T (pt) 2018-03-27

Family

ID=49712374

Family Applications (2)

Application Number Title Priority Date Filing Date
PT172084089T PT3366293T (pt) 2012-06-07 2012-06-07 Di-hidronaftiridinas e compostos relacionados úteis como inibidores de cinase para o tratamento de doenças proliferativas
PT128783214T PT2858646T (pt) 2012-06-07 2012-06-07 Di-hidronaftiridinas e compostos relacionados úteis como inibidores de cinase para o tratamento de doenças proliferativas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT172084089T PT3366293T (pt) 2012-06-07 2012-06-07 Di-hidronaftiridinas e compostos relacionados úteis como inibidores de cinase para o tratamento de doenças proliferativas

Country Status (26)

Country Link
EP (3) EP2858646B1 (pt)
JP (1) JP5883195B2 (pt)
KR (1) KR101652229B1 (pt)
CN (3) CN110403938A (pt)
AU (1) AU2012327210B2 (pt)
BR (1) BR112014030577B1 (pt)
CA (1) CA2875970C (pt)
CY (1) CY1123377T1 (pt)
DK (2) DK2858646T3 (pt)
ES (2) ES2797252T3 (pt)
FR (1) FR22C1013I2 (pt)
HK (1) HK1209345A1 (pt)
HR (1) HRP20200864T1 (pt)
HU (2) HUE049958T2 (pt)
IL (1) IL236110A (pt)
LT (2) LT3366293T (pt)
MX (2) MX2014015024A (pt)
NO (1) NO2022010I1 (pt)
PH (2) PH12014502757B1 (pt)
PL (1) PL3366293T3 (pt)
PT (2) PT3366293T (pt)
RS (1) RS60406B1 (pt)
RU (1) RU2664055C2 (pt)
SG (1) SG11201408133TA (pt)
SI (1) SI3366293T1 (pt)
WO (1) WO2013184119A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
BR112015022191A8 (pt) 2013-03-15 2018-01-23 Celgene Avilomics Res Inc compostos heteroarila e usos dos mesmos
ES2892423T3 (es) 2013-03-15 2022-02-04 Celgene Car Llc Compuestos de heteroarilo y usos de los mismos
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
CN108473485B (zh) * 2016-01-11 2021-11-02 默克专利股份公司 喹啉-2-酮衍生物
CA3065365A1 (en) * 2017-05-30 2018-12-06 Daniel L. Flynn Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alpha
CN111094286B (zh) * 2017-09-20 2022-07-29 浙江海正药业股份有限公司 1,2-二氢-1,6-萘啶类衍生物、其制备方法及其在医药上的用途
CN111818915B (zh) * 2018-01-31 2024-05-24 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
US20220144825A1 (en) * 2019-03-11 2022-05-12 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
CA3138300A1 (en) 2019-05-03 2020-11-12 Kinnate Biopharma Inc. Inhibitors of raf kinases
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
EP4013412A1 (en) 2019-08-12 2022-06-22 Deciphera Pharmaceuticals, LLC Ripretinib for treating gastrointestinal stromal tumors
TW202128680A (zh) 2019-10-24 2021-08-01 美商奇奈特生物製藥公司 Raf激酶抑制劑
KR20220123057A (ko) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 비정질 키나아제 억제제 제형 및 이의 사용 방법
EP4084779A1 (en) 2019-12-30 2022-11-09 Deciphera Pharmaceuticals, LLC Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
KR102535840B1 (ko) * 2020-07-31 2023-05-23 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도
US11407737B2 (en) 2020-09-18 2022-08-09 Kinnate Biopharma Inc. Inhibitors of RAF kinases
US11377431B2 (en) 2020-10-12 2022-07-05 Kinnate Biopharma Inc. Inhibitors of RAF kinases
CN112625038A (zh) * 2020-12-31 2021-04-09 武汉九州钰民医药科技有限公司 制备瑞普替尼的方法
WO2022162690A1 (en) * 2021-01-28 2022-08-04 Dr. Reddy's Laboratories Limited Process for the preparation of ripretinib and solid state forms thereof
WO2022226261A1 (en) 2021-04-23 2022-10-27 Kinnate Biopharma Inc. Treatment of cancer with a raf inhibitor
WO2023122322A1 (en) * 2021-12-24 2023-06-29 Teva Pharmaceuticals International Gmbh Improved processes for the preparation of ripretinib
CN114213411B (zh) * 2022-01-24 2023-06-30 成都伊诺达博医药科技有限公司 一种瑞普替尼的合成方法
TW202342055A (zh) 2022-02-03 2023-11-01 美商奇奈特生物製藥公司 Raf激酶抑制劑
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06003996A (es) * 2003-10-08 2006-07-05 Irm Llc Compuestos y composiciones como inhibidores de la proteina cinasa.
DE102006030524A1 (de) * 2006-07-01 2008-01-03 Koch Transporttechnik Gmbh Verfahren und Vorrichtung zur Beseitigung von lockerem Material auf wellenförmigen Oberflächen gestampfter Kohle für die Verkokung
CN101553232A (zh) * 2006-09-14 2009-10-07 迪赛孚尔制药有限公司 用于治疗增殖性疾病的激酶抑制剂
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
EP2076513A1 (en) * 2006-10-20 2009-07-08 Irm Llc Compositions and methods for modulating c-kit and pdgfr receptors
JP5230755B2 (ja) * 2008-02-22 2013-07-10 アイアールエム・リミテッド・ライアビリティ・カンパニー c−kitおよびPDGFRキナーゼ阻害剤としてのヘテロ環化合物および組成物

Also Published As

Publication number Publication date
CN110433162A (zh) 2019-11-12
HRP20200864T1 (hr) 2020-08-21
LT3366293T (lt) 2020-07-10
PL3366293T3 (pl) 2020-09-21
PH12014502757A1 (en) 2015-03-02
EP2858646B1 (en) 2017-12-20
HUE049958T2 (hu) 2020-11-30
JP5883195B2 (ja) 2016-03-09
WO2013184119A1 (en) 2013-12-12
KR101652229B1 (ko) 2016-08-30
CA2875970A1 (en) 2013-12-12
BR112014030577A8 (pt) 2018-10-23
AU2012327210A1 (en) 2014-01-09
NO2022010I1 (no) 2022-04-07
LTPA2022008I1 (pt) 2022-05-25
CY1123377T1 (el) 2021-12-31
PH12014502757B1 (en) 2015-03-02
FR22C1013I2 (fr) 2022-12-30
HUS2200017I1 (hu) 2022-06-28
SI3366293T1 (sl) 2020-08-31
CN104902895B (zh) 2019-03-29
EP3722296A3 (en) 2020-10-21
IL236110A (en) 2016-11-30
FR22C1013I1 (fr) 2022-06-17
EP2858646A4 (en) 2015-09-02
IL236110A0 (en) 2015-01-29
CN104902895A (zh) 2015-09-09
MX2020005712A (es) 2022-05-17
KR20150053894A (ko) 2015-05-19
EP3722296A2 (en) 2020-10-14
DK2858646T3 (en) 2018-03-19
CA2875970C (en) 2017-07-04
RU2664055C2 (ru) 2018-08-14
EP3366293B1 (en) 2020-03-11
BR112014030577B1 (pt) 2022-02-08
RS60406B1 (sr) 2020-07-31
ES2797252T3 (es) 2020-12-01
JP2015520186A (ja) 2015-07-16
SG11201408133TA (en) 2015-01-29
PH12018502294A1 (en) 2020-11-04
MX2014015024A (es) 2015-07-06
AU2012327210B2 (en) 2016-07-28
ES2663605T3 (es) 2018-04-16
CN110403938A (zh) 2019-11-05
EP2858646A1 (en) 2015-04-15
EP3366293A1 (en) 2018-08-29
HK1209345A1 (en) 2016-04-01
PT3366293T (pt) 2020-06-18
DK3366293T3 (da) 2020-06-15
RU2014153920A (ru) 2016-07-27

Similar Documents

Publication Publication Date Title
HUS2200017I1 (hu) Dihidronaftiridinek és rokon vegyületek, amelyek hasznosak kináz inhibitorokként proliferatív betegségek kezelésére
HRP20171474T1 (hr) Triazolopirazini kao inhibitori brd4 za uporabu u liječenju raka
HK1200449A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases bub1
HK1207861A1 (en) Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1
PT3418281T (pt) Pirazolo[1,5-a]pirimidinas úteis como inibidores da quinase atr para o tratamento de doenças de cancro
HK1210174A1 (en) Serine threonine kinase inhibitors for the treatment of hyperproliferativediseases
HK1199814A1 (en) Inhibition of adaptor associated kinase for the treatment of pain
EP2887805A4 (en) COMPOUNDS AND METHOD FOR TREATING BLOOD HIGH PRESSURE
AP2014007905A0 (en) Novel compounds for the treatment of dyslipidemia and related diseases
HK1205500A1 (en) Kinase inhibitors for the treatment of cancer
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
IL231448A0 (en) Phosphatidylinositol 3-kinase inhibitors for cancer treatment
AU2012901199A0 (en) Kinase inhibitors for the Treatment of Cancer